Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
Related Content
-
Sickle Cell Disease CoalitionThe Sickle Cell Disease Coalition (SCDC)...
-
Andra James, MD, MPHDr. James is an OB-GYN consultant and a ...
-
New England Pediatric Sickle Cell ConsortiumThe New England Pediatric Sickle Cell Co...
-
Julie A. Panepinto, MD, MSPHJulie Panepinto is the Director of the D...
-
Individualized pain plans significantly reduce hospitalization in pediatric sickle cell patients with vaso-occlusive...Background: Vaso-occlusive crisis (VOC)...
-
Dental Health in Children with Sickle Cell DiseaseWhat is Sickle Cell Disease? Sickle Cel...
-
2019 WEPSCF Rockin’ the Red – 14th Annual FundraiserJoin us as we celebrate National Sickle ...